Voclosporin-based, triple-immunosuppressive therapy vs high-dose glucocorticoid-based dual-immunotherapy for lupus nephritis: A propensity analysis (ERA-EDTA 2024) - Mar 23, 2024 - Abstract #468; Pres time: May 25, 2024; 12:00 PM - 12:10 PM; Location: The Square; "An integrated analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies concluded that combining voclosporin with lower-dose mycophenolate mofetil (MMF, 2 g/day) and low-dose glucocorticoids (GCs) led to significantly greater and earlier reductions in proteinuria when compared to MMF and GCs alone...Yet, dual-immunosuppressive regimens consisting of high-dose glucocorticoids and either intravenous cyclophosphamide (IVC) or higher doses of MMF (>2 g/day) continue to be frequently used for the initial management of active LN despite their association with incomplete efficacy and dose-dependent toxicities... Voclosporin-based, triple immunosuppressive therapy was associated with an improved safety profile as well as greater and earlier reductions in proteinuria compared to more conventional dual immunosuppressive regimens. These data support treatment guidelines for active LN that recommend both minimizing patient exposure to GCs and use of a multi-targeted..."
Anemia • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Ernie Yap1; Anca Askanase2; Kenneth Kalunian3; Maria Dall'era4; Lucy Hodge1; Matt Truman1; Neil Solomons5
|